If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 281

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patie

Objective
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Hematologic/Blood Related Cancers

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Objective
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
Categories
Cancer, Ovary, Bladder, Gynecologic Cancers, Pancreas/Liver, Lip, Oral Cavity and Pharynx, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Esophagus, Thoracic Cancers, Early Phase/Multiple Disease Site Cancers

A Randomized, Open-Label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naïve Subjects with Advanced or Metastatic PD-L1 High (TPS >/= 50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION

Objective
This project is being done to gather information about Datopotamab Deruxtecan (Dato-DXd) in combination with Pembrolizumab versus Pembrolizumab alone in treating metastatic NSCLC.
Protocol No
DAIICHI-DS1062-A-U304
Categories
Cancer, Lung, Thoracic Cancers

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer, Colorectal, Gynecologic Cancers, Esophagus, Other Urologic, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Esophagus, Skin Cancers, Stomach, Prostate and Urologic Cancers, Pancreas/Liver, Breast Cancers, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Lung, Thoracic Cancers